Concurrent hereditary haemochromatosis and idiopathic Parkinson's disease: A case report series

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 75, Issue 4, 2004, Pages 631-633

  Costello, D J ^a   Walsh, S L ^a   Harrington, H J ^a   Walsh, C H ^b  

^a MERCY UNIVERSITY HOSPITAL   (Ireland)

^b SOUTH INFIRMARY VICTORIA UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

IRON;

ADULT; ARTICLE; BASAL GANGLION; CARDIOVASCULAR DISEASE; CASE REPORT; CEREBELLAR ATAXIA; CEREBROVASCULAR DISEASE; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GAIT DISORDER; GENETIC DISORDER; HEMOCHROMATOSIS; HUMAN; IDIOPATHIC DISEASE; MALE; NEUROLOGIC DISEASE; NEUROLOGICAL COMPLICATION; PARKINSON DISEASE; PRIORITY JOURNAL; RISK FACTOR; SYMPTOMATOLOGY;

BASAL GANGLIA; BASAL GANGLIA DISEASES; CEREBRAL INFARCTION; COMORBIDITY; DIAGNOSIS, DIFFERENTIAL; FEMALE; HEMOCHROMATOSIS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IRON; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; PARKINSON DISEASE; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 1642564597     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2003.027441     Document Type: Article

References (32)

1. Berg D, Hoggenmuller U, Hofmann E, et al. The basal ganglia in haemochromatosis. Neuroradiology 2000;42:9-13.
2. Schröder J, Haan J. Extrapyramidales Syndrom bei idiopathischer Hämochromatose (IHC). Nervenartz 1987;58:577-8.
3. Nielsen JE, Neerup Jensen L, Krabbe K. Hereditary haemochromatosis: a case of iron accumulation in the basal ganglia associated with a parkinsonian syndrome. J Neurol Neurosurg Psychiatry 1995;59:318-21.
4. Demarquay G, Setiey A, Morel Y, et al. Clinical report of three patients with hereditary haemochromatosis and movement disorders. Movement Dis 2000;15:1204-9.
5. Kuipers K. Over Haemochromatosis met hepato-cerebral degeneratie. These de Univ U J Enschede & Zonen Amsterdam Haarlem 1932.
6. Scully RE, Galdabini JJ, McNeely BU. Case records of the Massachusetts General Hospital: case 17-1979. N Engl J Med 1980;300:969-76.
7. Milder MS, Cook JD, Stray S, et al. Idiopathic haemochromatosis, an interim report. Medicine 1980;59:34-49.
8. Royden Jones Jr H, Hedley-Whyte ET. Idiopathic haemochromatosis (IHC): Dementia and ataxia as presenting signs. Neurology (Cleveland) 1983;33:1479-83.
9. Harvey RJ, Summerfield JA, Fox NC, et al. Dementia associated with haemochromatosis: a report of two cases. Eur J Neurol 1997;4:318-22.
10. Rajput AH, Offord KP, Beard CM, et al. Epidemiology of Parkinsonism: incidence, classification and mortality. Ann Neurol 1984;16:278-82.
11. McDonnell SM, Preston BL, Jewell SA, et al. A survey of 2851 patients with haemochromatosis: symptoms and response to treatment. Am J Med 1999;106:619-24.
12. Riederer P, Dirr A, Goetz M, et al. Distribution of iron in different brain regions and subcellular compartments in Parkinson's disease. Ann Neurol 1992;32:S101-4.
13. Hallgren B, Sourander P. The effect of age on the nonhaemin iron in the human brain. J Neurochem 1958;3:41-51.
14. Octave JN, Schneider YJ, Trouet A, et al. Iron uptake and utilisation by mammalian cells. I: Cellular uptake of transferrin and iron. Trends Biochem Sci 1983;8:217-20.
15. Youdim MBH, Ben-Shochar D, Riederer P. Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration? Acta Neurol Scand 1989;26:47-54.
16. Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem 1992;59:1609-23.
17. Zhou B, Westaway SK, Levinson B, et al. A novel panthothenate kinase gene (PANK2) is defective in Hallervoden-Spatz syndrome. Nat Genet 2001;28:345-9.
18. Attieh ZH, Mukhopadhyay CK, Seshadri V, et al. Ceruloplasmin ferroxidase activity stimulates cellular iron uptake by a trivalent cation-specific transport mechanism. J Biol Chem 1999;274:1116-23.
19. Mukhopadhyay CK, Attiah ZK, Fox PL. Role of ceruloplasmin in cellular iron uptake. Science 1998;279:714-17.
20. Gitlin JD. Aceruloplasminemia. Pediatr Res 1998;44:271-6.
21. Curtis ARJ, Fey C, Morris CM, et al. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat Genet 2001;28:350-4.
22. Earle KM. Trace metals in Parkinson's disease. J Neuropathol Exp Neurol 1968;27:1-14.
23. Dexter DT, Wells FR, Lees AJ, et al. Increased nigral iron content in postmortem parkinsonian brain. Lancet 1987;2:1219-20.
24. Sofic E, Riederer P, Heinsen H, et al. Increased iron (III) and total iron content in post-mortem substantia nigra of porkinsonian brain. J Neurol Transm 1988;74:199-205.
25. Riederer P, Sofic E, Rausch W, et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 1989;52:515-20.
26. Gorell JM, Ordidge RJ, Brown GG, et al. Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology 1995;45:1138-43.
27. Gerlach M, Ben-Shachar D, Riederer P, et al. Altered brain metabolism as a cause of neurodegenerative diseases? J Neurochem 1994;63: 793-807.
28. Ostrerova-Golts N, Petrucelli L, Hardy J, et al. The A53T α-synuclein mutation increases iron-dependent aggregation and toxicity. J Neurosci 2000;20:6048-54.
29. Cammermeyer J. Deposition of iron in paraventricular areas of the human brain in haemochromatosis. Neuropathol Exp Neurol 1947;2:111-27.
30. Sheldon JH. The iron content of the tissues in haemochromatosis, with special reference to the brain. Q J Med 1927;21:123-37.
31. Morgan EH. Iron and transition metal transport into the brain. Alfred Benzon symposium: brain barrier systems. 1999;45:357-70.
32. Moos T, Morgan EH. Brain iron homeostasis. Alfred Benzon symposium: brain barrier systems. 1999;45:371-86.